Delivery Order SPE2DB22D2206-SPE2DB23FJS16
Award Date 8/9/23
Potential Completion Date 8/10/23
Potential Value $7.2K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $12,109.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Neulasta 6 mg/0.6 ml syringes on September 26, 2025, with completion scheduled for September 29, 2025. This non-set-aside contract represents a routine pharmaceutical procurement from the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $10,026.36 for Neulasta 6 mg/0.6 mL syringes, with completion targeted for August 7, 2025. The contract, issued on August 6, 2025, utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,389.54 to AmerisourceBergen Drug Corp for the supply of Neulasta Onpro 6 mg/0.6 ml injectable kits, with an ultimate completion date of December 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,231.59 to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits on December 2, 2025, with completion scheduled for December 3, 2025. This firm fixed-price, non-set-aside delivery order represents a pharmaceutical supply transaction under a competitively awarded contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $27,011.21 to AmerisourceBergen Drug Corp for the supply of Neulasta OnPro 6 mg/0.6 ml kits on August 29, 2025, with completion scheduled for September 2, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader relationship with the federal government. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $11,779.71 to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits on December 19, 2025, with completion scheduled for December 22, 2025. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical supply delivery. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,505.98 delivery order to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits, with an ultimate completion date of June 3, 2025. This non-set-aside, firm fixed-price contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's broader pharmaceutical supply agreement with the federal government. This...
- The Defense Logistics Agency awarded a $11,686.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits, with an ultimate completion date of June 2, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,530.76 to AmerisourceBergen Drug Corp for Neulasta Onpro 6 mg/0.6 ml kits on September 9, 2025, with completion scheduled for September 10, 2025. The award utilized firm fixed pricing with no set-aside designation, indicating competitive selection among eligible contractors. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate...
- <p>The Defense Logistics Agency issued a $3,899.40 delivery order to Amerisourcebergen Drug Corp on March 25, 2026, for Neulasta 6 mg/0.6 ml syringes under its parent Indefinite Delivery Contract with the DLA Troop Support Medical.</p> <p>Place of performance is Conshohocken, PA. The order has a firm fixed price and ultimate completion date of March 26, 2026. No set-aside was used.</p>
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB23FJS16Delivery Order
The Defense Logistics Agency awarded a $7,195.68 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 6 mg/0.6 ml syringes of the drug Neulasta. Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, will deliver the pharmaceutical product to a location in Conshohocken, Pennsylvania by August 10, 2023 to support the Defense Logistics Agency's medical supply needs. No set aside designation or subcontractors were identified. The delivery order was issued against an existing DLA medical product supply vehicle and will provide needed quantities of Neulasta, a drug used to increase white blood cell counts in cancer patients undergoing chemotherapy.
Generated 12/20/23, 12:31 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 8/9/23 |